|Bid||3.4900 x 1100|
|Ask||3.5000 x 1400|
|Day's Range||3.4600 - 3.6200|
|52 Week Range||2.7100 - 8.4400|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OrganiGram Holdings (OGI) received a “buy” rating from Jefferies on October 11. However, the investment firm lowered its price for the stock.
At 2:00 PM ET, the S&P; 500 and the Dow Jones were up by 1.7%. Despite the surge in the equity market, the cannabis sector showed a mixed performance today.
Organigram Holdings Inc. (OGI) (OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that the Company was recognized at the Excellence in Manufacturing Consortium (“EMC”) Awards of Excellence ceremony in Toronto on October 9.
Much like investors who have pulled back from the highly anticipated IPOs of 2019, many buyers of cannabis stocks and ETFs may want to think again before they hold out for better times and suffer a series of additional downdrafts. The ETFMG Alternative Harvest ETF (MJ), a proxy for the cannabis market, has declined by 48% since March 19.
Organigram Holdings Inc. (OGI) (OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that a representative of the Company has assumed board positions with three international organizations committed to promote and foster global cannabis industry growth: The American Trade Association for Cannabis and Hemp, The Policy Center for Public Health & Safety (both U.S.-based) and the European Alliance for Medical Cannabis.
Yesterday, contents of an email circulated among OrganiGram employees revealed the company had shut down several cooling towers due to high bacteria counts.
NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI), parent company of Organigram Inc., today announces the broadcast of its audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. Organigram CEO Greg Engel, a 30-year veteran of the pharmaceuticals, biotech, consumer packed goods and cannabis sectors, joins NNW’s Stuart Smith in an interview that discusses the company’s dramatic growth within Canada and its strategic expansion on a global scale. As one of the original 15 Canadian cannabis companies focused on the medical cannabis space, Organigram has evolved to serve Canada’s adult recreational market and sees significant opportunity in the country’s upcoming legalization of edible and derivative products.
With the end of 2019 coming up, the climate is changing for the cannabis industry. Canada is getting ready to enact the second stage of its legalization drive, opening markets for CBD extracts, beverages, and edibles. The Canadian market is estimated to account for 12% of global marijuana sales by the end of this year. The scale of the US market compensates for the patchwork legalization landscape; US legal cannabis will account for 80% of global sales this year, according to Arcview Market Research.Troy Dayton, CEO of Arcview, sees CBD as the driver for cannabis sales through 2024. He says, “CBD products on the shelves of grocery stores and mass merchants is just the first act in the “Cannabinoids Everywhere” phenomenon. Unlike with alcohol, coffee or other plant-sourced consumables, cannabis product marketers have more than taste and strength to work with; they also have the subtle effects of 100-plus cannabinoids other than THC. The popularity of CBD is the first inkling of things to come.”In a report released earlier this summer, retail data analytics firm Nielsen points out that the initial legalization cannabis focused on dried flower products but that the upcoming wave of new derivative products, oils, edibles, and drinks have both higher gross margins and no supply chain bottlenecks. The Nielsen report predicts the US cannabis market reaching $41 billion by 2025.So, with the market primed to expand, it’s clear that there is a lot of money to be made in marijuana stocks. The segment’s recent dip – at least three major players are at one-year lows as of yesterday – offers a savvy investor a chance to buy in at low prices and high upside potential. We’ve used TipRanks’ Stock Screener tool to find three small-cap marijuana companies with well over 100% upside potential. Let's take a closer look:Green Thumb Industries Chicago-based Green Thumb (GTBIF – Get Report) owns the Rise and Essence brands of retail cannabis outlets, with more than 50 retail stores under the Rise name and additional outlets through third-party marketers. Green Thumb’s calendar Q2 earnings release showed $44.7 million in revenues, a 60% sequential gain and a 228% year-over-year gain. Organic consumer product growth and increased store traffic powered the revenue gains. Along with fast-growing revenue, the company also boasts a strong cash position, with $83 million in liabilities more than balanced by $117 million cash on hand. CEO Ben Kolver stated of the company’s forward prospects, “Continued execution of key priorities such as… accelerated store openings, and expanded distribution of our brand portfolio, sets us up well for the future.”With operations in 12 US states, including its retail locations and 13 manufacturing facilities, Green Thumb is well positioned to take advantage of the expansion prospects in the US cannabis markets.Starting coverage of Green Thumb for Cowen in mid-September, 5-star analyst Vivien Azer specifically cites the company’s high growth potential. She writes, “We believe the company's focused operating model that favors geographic depth, and a balanced revenue approach between wholesale and retail, gives GTI the most revenue and margin potential among our MSO coverage. GTI is our favorite name among the MSOs.” Azer’s $18.50 price target suggests an upside to this stock of 122%. Ms. Azer adds that Green Thumb is a “compelling buy,” describing it as, “…currently trading at 4.2x FY20 revenue, which is a 22% discount to their MSO peers.” (To watch Azer's track record, click here)The company’s low share price and high upside are key benefits for new investors looking to get in on that expansion. GTBIF sells for just $8.30 cents per share, and the average price target, $19.75, indicates room for 138% growth. Green Thumb’s Strong Buy analyst consensus rating is based on a unanimous 7 buys assigned to the stock in the last three months. (See Green Thumb's price targets and analyst ratings on TipRanks)Supreme Cannabis CompanyFormerly Supreme Pharmaceuticals, Supreme Cannabis (SPRWF – Get Report) in September reported its fiscal Q4 number, which included sales growth of 436%, to C$19 million, and the company’s first quarterly profit of C$3.2 million. Company statements credit the high-margin strategy of focusing on premium cannabis products, and the success of its 7ACRES brand of recreational marijuana. More importantly, however, the company held production-related overhead costs down to 49% of net revenue. With sales expected to rise, the company’s firm control of costs is boon for investors.Supreme posted a C$41 million profit for fiscal 2019, and projects fiscal 2020 profits to come in between C$150 million and C$180 million. The company is positioning itself in partnership with PAX Labs, a leading provider of vaping products to the Canadian markets, giving it a foot in the door when the ‘Cannabis 2.0’ wave hits Canada later this year.CIBC analyst John Zamparo is impressed by Supreme’s niche in the cannabis industry. Initiating coverage of the stock, he writes, “Supreme Cannabis' focus on existing, premium-seeking consumers may be the most effective and yet somehow neglected strategy in the adult-use cannabis space.” Zamparo further notes that “…top-quality flower retains higher prices and is more defensive against margin compression, supporting Supreme's strategy.”With a marketing strategy based on premium product, and a compelling valuation, Zamparo gives SPRWF a buy rating and a C$2 price target. His target implies an upside of 79%. (To watch Zamparo's track record, click here)Zamparo is not along in seeing high potential in Supreme Cannabis. Canaccord 4-star analyst Matt Bottomley also initiated coverage of the stock after the earnings report, giving it a buy rating based on the solid numbers. His C$2.30 price target suggests a 107% upside for Supreme.Overall, Supreme Cannabis has a Strong Buy from the analyst consensus, based on 3 recent buy ratings. The stock is prided at a bargain, only $0.84 US, and the $2.17 average price target suggests a robust upside of 178%. (See Supreme Cannabis' price targets and analyst ratings on TipRanks)OrganiGram HoldingsOur third small-cap cannabis producer is unique. Unlike most of the Canadian marijuana producers, OrganiGram (OGI – Get Report) is based in New Brunswick, among the country’s Atlantic Maritime Provinces. And, in another departure from the cannabis norm, OrganiGram has operations in all 10 of Canada’s provinces, making it one of the few cannabis companies with a presence coast-to-coast. Most of the Canadian cannabis companies are focusing their operations on the populous regions of Ontario, Alberta, and British Columbia; OrganiGram’s foothold in the Atlantic Maritimes gives it a link to the Canadian region with the country’s highest adult-use rates. The Martimes give OrganiGram a low-competition base region, providing steady sales to support expansion in the rest of the country.OrganiGram also differentiates itself from its peers in its production methods. Most growers measure their production facilities by square footage, expanding the footprint to increase production area. OrganiGram grows vertically; in the words of CEO Greg Engel, “Where the majority of companies went with large green house expansions, our facility is three levels. We actually do vertical cultivation.” Growing vertically allows OrganiGram to get the greatest efficiency out of its 14-acre facility in Moncton, New Brunswick. The company expects to reach a production capacity of 113,000 kilograms per year by December. At that capacity, OrganiGram will enter the top-10 of Canadian cannabis producers.OrganiGram’s strong background and increasing production capacity has brought it high ratings from the Street’s analysts. Writing from Beacon Securities, Russell Stanley says the additions to the grow facility “…demonstrate continued execution against the company’s expansion plan, setting the stage for significant revenue/EBITDA growth in fiscal 2020.” He adds that the company reported C$3 million cash on the books in the last quarter, and looks forward to November’s fiscal Q4 report. Stanley’s C$15 price target suggests a one-year upside of 220% for OGI shares. (To watch Stanley's track record, click here)John Zamparo, quoted above on Supreme Cannabis, is also bullish on OGI. He writes, “The company offers one of the few opportunities to gain exposure to the cannabis space at a reasonable price. We believe Organigram has demonstrated track record of profitability, a rarity in the cannabis sector.” With profitability in mind, Zamparo initiated coverage of OGI at C$9, indicating confidence in a 92% upside.Like the stocks above, OrganiGram also has a Strong Buy from the analyst consensus. This rating is derived from 8 buys and 1 hold given in the past three months. The stock trades for $3.54, and the average price target of $9.40 suggests a hefty upside potential of 183%. (See OrganiGram's price targets and analyst ratings on TipRanks)
KushCo Holdings' consensus target price has fallen from $8.40 on May 30 to $7.44 as of September 27. The decline shows analysts’ weaker sentiments.
Organigram Holdings (OGI – Get Report) is putting its pieces together at the right time. As the sentiment for the cannabis industry has temporarily turned negative, the company dropped the ball in the last quarter on its changing of growing protocalls, emerging improvements at the Canadian provincial and national governments, and it prepares for the upcoming legalization of derivative cannabis product sales in Canada.Getting ready to goThere are several things Organigram has done to position itself for a rebound in the cannabis sector, including its partnership with leading vape company PAX Labs, its $10 million investment in Hyasynth Biologicals, and another $15 million investment a chocolate production line.The investment in Hyasynth Biologicals is particularly compelling because it involves cannabinoid biosynthesis, which represents a potentially high level of disruption in the sector. This will take longer to pay off, cut it has a lot of probable upside to it.As for vapes and edibles, these are among the top expected sales leaders when companies are allowed to start to sell them, which should be in the last couple of weeks in December, even though they'll be officially approved in October. That means the full results won't show up in its earnings report until the first calendar quarter of 2020; that'll be true of all Canadian-based cannabis firms.Costs of dried flower will fall back down to normalWhen Organigram decided to change its growing protocols, it ended up being a temporary disaster, as the results in a smaller test weren't able to be reproduced when went with a larger planting regimen when operating under real-world conditions.The result was for its market-leading cost per gram of dried flower jumped from a range of $0.65 and $0.95 per gram in second quarter of 2019, to a much higher range of $0.95 and $1.29 per gram in the third quarter.In response to the poor results, the company has quickly reverted to the way it grew cannabis in the past, and expects the cost per gram to drop back to former levels. Over the last five quarters quarters Organigram's cost per dried flower gram averaged approximately $0.90.Considering it's going to go back to prior costs per gram and it's preparing to sell into a much higher-margin derivatives market, starting in the latter part of 2019 and fully, into 2020, the company should generate some impressive results in fiscal 2020. Gross margins are among the best in the industry, and should continue to maintain that high level of performance.Raymond James analyst Rahul Sarugaser recently initiated coverage on Organigram, and sees net revenues increasing from $97 million in fiscal 2019 to about $552 million in fiscal 2024, when sees Canadian cannabis sales reaching $6 billion. His EBITDA projection for 2019 is $36 million, and 2020 he sees it jumping to $87 million.Consensus VerdictOverall, this cannabis player stands as a 'Strong Buy' name among Wall Street analysts. In the last three months, OGI has won eight 'buy' ratings along with one 'hold.' With a return potential of over 150%, the stock's consensus price target lands at $9.36. (See OGI's price targets and analyst ratings on TipRanks)ConclusionTo say the legalization of cannabis in Canada has been disappointing at this point would be an understatement. A lot of that must be directly attributed to Health Canada and the parameters its working within.The number of licenses rewarded to retailers is far behind expectations, and some that have received their licenses, to this day, haven't even started to construct their buildings. That has led to Health Canada changing the rules for those applying for licenses, but that does nothing in the short term to deal with the problem.Even so, there is finally some movement in Toronto and Ontario, where there should be another 50 stores to sell from in the near future. That will help, but it's still far too small for a region that has millions of potential customers.The good news there is it's only going to get better, and with Organigram starting to complete some of its facilities which will boost production, the timing couldn't be better.In early September Organigram received approval from Health Canada to boost its overall production capacity to 76,000 kilograms annually.Presumably this additional scale will bring down costs per gram even further, generating even better profitability.The first harvest in this new rooms is expected to come in November, just in time to meet the upcoming demand for wider-margin derivative products. I'm not saying that specific product will be used to make derivatives, but it can be used to meet the needs of its existing customers while its current harvests are being made into derivatives. the company sees dried flower from the new harvest to be available for sale by fiscal fourth quarter that ends February 2020.In Phase 5 of the current expansion the company will have more extraction capacity for a edibles and derivative product facility.For these reasons, Organigram looks like it's going to outperform over the next couple of years. This is a good time to take a position because of the correction in the cannabis sector which has driven down share prices. Once the rebound begins, we're unlikely to see prices this low for a long time, if ever.Visit TipRanks’ Trending Stocks page, and find out what companies Wall Street’s top analysts are looking at now.
The most popular cannabis stocks rallied as much as 20% from washed-out levels that one analyst identified as “capitulation lows” on Aug. 28. Cannabis vapes are often implicated. First, very bullish developments for cannabis companies are about to play out in Canada.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2019) - On national TV Sat. Sept. 28 & Sun. Sept. 29, 2019 - As the Canadian cannabis sector remains strong, BTV- Business Television visits thriving opportunities ripe for investment.Click company name to watch their feature:Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) - With insight from David Kideckel, Managing Director and Senior Equity Research Analyst, Healthcare & Life Sciences at AltaCorp. BTV drops in on one ...
Canopy Growth (NYSE:CGC) has bounced back by 16.3% so far in September after a brutal sell-off over the past few months. I recommended Canopy Growth stock back on Au. 30. I felt the stock had been oversold given how little its fundamental picture has changed.Source: Shutterstock A brand new report on Canadian cannabis market share seems to confirm the idea that Canopy is dominating the nascent Canadian market. Experienced investors know a first-mover advantage is extremely valuable in the long-term.One of the biggest reasons why CGC stock has dropped in the past few months is because its losses have been heavier than expected. However, the early market share numbers suggest Canopy's strategy of aggressively investing in ramping up its business is already paying off.InvestorPlace - Stock Market News, Stock Advice & Trading Tips The NumbersBank of America found Canopy has a 25% market share of all cannabis listings in Canada. The study included 1,980 listings, 101 brands and 39 different cannabis producers. * 10 Stocks to Sell in Market-Cursed September Canopy Growth Corp has the largest share of the Canadian market by a long shot. Analyst Christopher Carey says Canopy's market share is roughly double the 13% market share of its closest competitors, Aurora Cannabis (NYSE:ACB) and Organigram (NASDAQ:OGI).Carey says establishing that first-mover advantage is critical."Establishing distribution - early and big - can be significant in creating long-term market share moats for a business competing in new consumer categories prone to fragmentation," he said.Unfortunately, the market share study wasn't all good news for Canopy Growth stock. The 25% "share of listings" represents product already on shelves throughout Canada. Bank of America also looked at "sell-in," or total retail purchases of cannabis. Sell-in represents the future share of listings. In that statistic, Canopy has dropped to second place with 22%, trailing Aurora at 27%. The Future of CannabisCarey says investors shouldn't get too worried about Canopy losing sell-in share. In the June quarter, Canopy's harvest jumped 183% quarter-over-quarter, much of which was hot-selling THC flower.Carey is expecting this spike in harvest will translate to a 33% quarterly increase in Canopy sell-in in the fiscal second quarter of 2020. That big push could push Canopy back ahead of Aurora in sell-in share.Obviously having that top market share spot is ideal, but as long as Canopy remains at or near the top, investors should be rewarded in time. Certainly, investors want Canopy Growth to be the Coca-Cola (NYSE: KO) of cannabis, but it will be just fine if Canopy Growth stock ends up the PepsiCo (NASDAQ: PEP) of Canadian cannabis.In fact, PEP stock has generated a total return of more than 2,630% over the past 30 years. KO stock has a total return of 2,570% in that time. How to Play Canopy Growth StockThe latest Canadian market share numbers were certainly good enough to keep Carey in the bull camp when it comes to CGC stock."Canopy remains a company, if a still imperfect story, with a chance at becoming a leading global player in cannabis, especially given its industry leading [balance] sheet and partnership," he said.Bank of America has a "buy" rating and $27.66 price target for Canopy Growth stock.If you are a cannabis investor that believes the industry is just getting started, I think you can't go wrong owning Canopy Growth stock. My only recommendation would be to hedge your bets by owning ACB stock and at least two or three other cannabis stocks as well.As much as you love Canopy Growth stock and think Canopy will end up as the Coke or Pepsi of cannabis, it is still extremely early in the cannabis game. Especially in the event of U.S. legalization, there will be plenty of demand to support multiple market winners.It's likely most of the smaller names can't beat out Canopy Growth Corp and Aurora directly. But they might make appealing buyout targets down the line.I would recommend all cannabis investors buy Canopy Growth stock, ACB stock and at least two more of their favorite cannabis plays for a more diversified approach to the market.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post Canopy Growth Stock Needs to Be One of Your Main Cannabis Plays appeared first on InvestorPlace.
After a weak couple of months, cannabis stocks rallied in the first week of September . That rally seems to have stalled so far in the second week of the month. S3 Partners analyst Ihor Dusaniwsy said ...
Organigram Holdings Inc. (NASDAQ: OGI ) (TSX: OGI) said Monday it has obtained approval from Health Canada for the licensing of 17 cultivation rooms under the Cannabis Regulations. The licensing of these ...
Organigram Holdings Inc. (OGI) (OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that effective September 6, 2019 it has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations. The new cultivation rooms represent approximately 15,000 kg/yr1 of increased target production capacity.
Cannabis ETFs the ETFMG Alternative Harvest ETF and the Horizons Marijuana Life Sciences Index ETF were up 2.0% and 1.7%, respectively, at 1:20 PM today.
Shares of OrganiGram Holdings Inc. rose 2.3% in morning trading Thursday, after Oppenheimer analyst Rupesh Parikh started research coverage of the Canada-based cannabis company, with a perform rating. Parikh did not issue a stock price target. At Oppenheimer, a perform rating means the analyst expects the stock to perform "in line" with the S&P 500 within the next 12-to-18 months. "Over the past few quarters, the company has executed quite well generating positive EBITDA [earnings before interest, taxes, depreciation and amortization], which represents a standout performance amongst Canadian players," Parikh wrote in a note to clients. "Early success in the Canadian market coupled with above-peer financial delivery gives us confidence in the company's ability to further ramp from here." However, he has a "muted" outlook for the stock in the near term, given industry headwinds, elevated analyst forecasts and increased risks associated with the advanced products launch given recent adverse press on vaping. The Nasdaq-listed stock has tumbled 39.8% over the past three months, while the ETFMG Alternative Harvest ETF has dropped 21.7% and the S&P 500 has gained 5.4%.